Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : 2014 Biotech Charity Contest -- Ignore unavailable to you. Want to Upgrade?

To: rkrw who wrote (299)	4/22/2014 4:03:50 PM
From: Biotech Jim	Read Replies (1) \| Respond to of 487

Because the Zafgen drug is an injectable? Or because it has all the Ph3 work ahead of it, as well as finding a partner to do the heavy lifting? The difficulty of VVUS in its sales and general acceptance by primary care physicians to write scripts is problematic for all players in this field. How about OREX and its upcoming AdCom? How about the bonus of positive cardiac outcomes for any of these players; seems like OREX and VVUS have the best chance for this. Will that change the docs view for writing scrips?